<DOC>
	<DOCNO>NCT02575859</DOCNO>
	<brief_summary>The prognosis peritoneal metastases colorectal cancer recently improve cytoreductive surgery hyperthermic intraperitoneal chemotherapy ( HIPEC ) . Although outcomes improve early stage peritoneal metastasis treat , adjuvant HIPEC yet thoroughly address . This prospective pilot study assess feasibility , safety efficacy HIPEC perform simultaneously primary curative surgery colorectal cancer patient primary tumor-related risk-factors development metachronous peritoneal metastasis .</brief_summary>
	<brief_title>Adjuvant HIPEC Prevent Colorectal Peritoneal Metastases High-risk Patients</brief_title>
	<detailed_description>BACKGROUND Peritoneal surface second common site disease progression colorectal cancer ( CRC ) , follow liver metastasis . Historically , prognosis CRC peritoneal metastasis ( PM ) 6 month palliative systemic chemotherapy supportive care . Survival improvement report cytoreductive surgery hyperthermic intraperitoneal chemotherapy ( CRS/HIPEC ) . However , CRS/HIPEC effective safe early-stage CRC-PM treat patient suitable CRS/HIPEC , due extensive peritoneal and/or systemic disease . Also , palliative setting , modern systemic therapy appear less effective PM , non-PM metastatic CRC absence symptom current limitation image hamper early diagnosis treatment PM . These point would support use adjuvant HIPEC prevent outgrowth occult peritoneal seed macroscopic disease . STUDY DESIGN This tudy assess feasibility safety integrate approach curative surgery adjuvant HIPEC perform time primary surgery patient primary CRC high risk development metachronous PM . Patients prospectively select base preoperative clinical radiological work-up . At surgery , careful exploration peritoneal cavity , intra-operative pathological examination carry confirm clinical-pathological risk-factors PM development Standard adjuvant systemic chemotherapy intend postoperative setting . A matched control group select among patient colorectal cancer undergo curative surgery standard adjuvant systemic chemotherapy institution period . STUDY POPULATION Patients colorectal cancer undergo intentionally curative resection primary tumor infiltrate visceral serosa ( T4a ) directly invade adjacent organ ( T4b ) , positive peritoneal wash cytology resect ovarian minimal peritoneal metastasis . INTERVENTION Adjuvant HIPEC procedure perform general anaesthesia completion surgical procedure . Colon resection primary tumor perform accord oncologic principle adequate lymph-adenectomy.Greater less omentectomy adhesiolysis ( necessary ) perform routinely ensure optimal perfusion HIPEC . Tumor deposit visceral parietal surface surgically remove formal peritonectomy procedure and/or organ resection , need . HIPEC perform cisplatin ( 25 mg/m2/l perfusate ) mitomycin-C ( 3•3 mg/m2/l perfusate ) 42•5°C 60 minute accord closed-abdomen .technique . OUTCOMES Primary end-point sensitivity false positive rate preoperative/intraoperative assessment primary tumor-related risk-factors development peritoneal metastasis patient colorectal cancer undergo curative surgery..Secondary endpoint number participant adverse event measure safety tolerability , Cumulative incidence PM , overall progression-free survival assess comparison match control .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>pathologically confirm colorectal carcinoma ; curative surgery ; presence least one follow riskfactors development metachronous PM : minimal synchronous PM ( nodule ≤1cm omentum and/or close primary tumor ) , completely resected time primary tumor ; synchronous ovarian metastasis , also resect time primary tumor ; primary tumor either penetrate visceral peritoneum ( T4a ) , primary tumor directly invade organ ( T4b ) ; signature inform consent form . intention start adjuvant systemic therapy postoperative followup ; performance status ≤2 accord Eastern Cooperative Oncology Group score ; significant comorbidities . active sepsis impair cardiac function ( history previous cardiac failure , ejection fraction &lt; 40 % ) impair renal function ( serum creatinin &gt; 1.5 normal value creatinin clearance &lt; 60 mL/min ) ; impair hepatic function ( serum glutamic oxaloacetic transaminase , serum glutamic pyruvic transaminase , bilirubin &gt; 1.5 normal value ) ; impair bone marrow function ( leucocytes &lt; 4000/mm3 ; neutrophil &lt; 1500/mm3 ; platelet &lt; 80000/mm3 ) impair lung function ( diagnosis severe chronic obstructive pulmonary disease , force expiratory volume one second &lt; 50 % diffusion capacity lung carbon monoxide &lt; 40 % age adjust ) . extensive PM ( nodule &gt; 1cm , and/or nodule outside omentum and/or beyond close vicinity primary tumor ) ; extraabdominal/hepatic metastasis ; emergency presentation ( bleeding , perforate , occlusive primary ) ; bleed diathesis coagulopathy history previous neoplasm past three year , exclude skin spinocellular/basocellular carcinoma ; preoperative pelvic radiochemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIPEC</keyword>
	<keyword>peritoneal lavage</keyword>
</DOC>